



Novel aspects of corneal angiogenic and lymphangiogenic privilege

David Ellenberg^a, Dimitri T. Azar^{a,*}, Joelle A. Hallak^a, Faisal Tobaigy^b, Kyu Yeon Han^a, Sandeep Jain^a, Zhongjun Zhou^c, Jin-Hong Chang^{a,*}

^aDepartment of Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, University of Illinois at Chicago, 1855W. Taylor Street, Chicago, IL, USA

^bDepartment of Ophthalmology, Harvard Medical School, Boston, MA, USA

^cDepartment of Biochemistry, The University of Hong Kong, Hong Kong

ARTICLE INFO

Article history:

Available online 11 January 2010

ABSTRACT

In this article, we provide the results of experimental studies demonstrating that corneal avascularity is an active process involving the production of anti-angiogenic factors, which counterbalance the pro-angiogenic/lymphangiogenic factors that are upregulated during wound healing. We also summarize pertinent published reports regarding corneal neovascularization (NV), corneal lymphangiogenesis and corneal angiogenic/lymphangiogenic privilege. We outline the clinical causes of corneal NV, and discuss the angiogenic proteins (VEGF and bFGF) and angiogenesis regulatory proteins. We also describe the role of matrix metalloproteinases MMP-2, -7, and MT1-MMP, anti-angiogenic factors, and lymphangiogenic regulatory proteins during corneal wound healing. Established and potential new therapies for the treatment of corneal neovascularization are also discussed.

Published by Elsevier Ltd.

Contents

1. Introduction	209
2. Clinical causes of corneal neovascularization	211
3. Corneal avascularity and angiogenic/lymphangiogenic privilege	212
3.1. The balance of angiogenic and anti-angiogenic factors in the cornea	212
3.2. The limbus and the limbal barrier: questionable role in corneal angiogenic privilege	215
4. Molecular and cellular mechanisms of corneal NV	217
4.1. Corneal angiogenesis (hemangiogenesis)	217
4.2. Corneal lymphangiogenesis	217
5. Major angiogenic proteins of the cornea	217
5.1. Vascular endothelial growth factor (VEGF-A)	217
5.2. Basic fibroblast growth factor (bFGF)	218
5.3. Angiogenic pathways (VEGF and bFGF): distinct but intersecting	218
6. Additional angiogenesis regulatory proteins of the cornea	219
6.1. Decorin	220
6.2. Ephrins and Eph receptors	220
6.3. Activin receptor-like kinase	223
6.4. Integrins	223
7. Matrix metalloproteinases in the cornea	223
7.1. Matrix metalloproteinase-2 (MMP-2)	225
7.2. Matrix metalloproteinase-7 (MMP-7)	226
7.3. Membrane-type 1 metalloproteinase (MT1-MMP)	228
7.4. MT1-MMP interactions with VEGF and FGF	229
8. Inhibitors of angiogenesis in the cornea	229
8.1. Basement membrane-derived inhibitors of angiogenesis	229

* Corresponding authors. Tel.: +1 312 996 6590; fax: +1 312 996 7770.

E-mail addresses: dazar@uic.edu (D.T. Azar), changr@uic.edu (J.-H. Chang).

8.1.1.	Endostatin, neostatin, restin	229
8.1.1.1.	Endostatin	229
8.1.1.2.	Neostatin-7/-14	231
8.1.1.3.	Restin	231
8.1.2.	Arresten, canstatin, and tumstatin	232
8.2.	Plasminogen-derived and serine protease inhibitors of angiogenesis	233
8.2.1.	Angiostatin	233
8.2.2.	Pigment epithelium-derived factor (PEDF)	233
9.	Lymphangiogenesis regulatory proteins of the cornea	234
9.1.	VEGF-C/-D	235
9.2.	Endothelin-1	235
9.3.	Angiopoietin-1	236
10.	Clinical therapy of corneal angiogenesis and lymphangiogenesis	236
10.1.	Clinically-approved medical therapies	237
10.1.1.	Anti-inflammatory agents	237
10.1.2.	Bevacizumab	237
10.2.	Alternative medical therapies	238
10.2.1.	Propolis extract	238
10.2.2.	Epigallocatechin-3-gallate	238
10.2.3.	Resveratrol	238
10.3.	Vitamin D	238
10.4.	Promising potential medical therapies	238
10.4.1.	Endostatin and neostatins	238
10.4.2.	Anti-VEGFR-3 antibody	238
10.4.3.	“Non-bevacizumab” anti-VEGF-A antibody	239
10.4.4.	Anti-VEGFR-2 antibody	239
10.4.5.	Soluble VEGFR-3	239
10.4.6.	VEGFR-3 inhibitor	239
10.4.7.	Inhibitors of VEGFR-2 and VEGFR-3 signal pathways	239
10.4.8.	Platelet derived growth factor-B (PDGF-B)	239
10.5.	Surgical interventions for corneal angiogenesis and lymphangiogenesis	240
11.	Future directions	240
	Acknowledgement	240
	References	240

1. Introduction

Angiogenesis is the process by which new blood vessels derive from pre-existing ones. First termed in 1787 (Folkman, 2008), angiogenesis remains an incompletely understood process that involves the interaction of multiple cell types, including endothelial cells, pericytes, and circulating cells, as well as parenchymal cells and stromal cells (Penn et al., 2008). It was not until three decades ago that major *in vivo* angiogenesis models were developed for testing potential therapeutic drugs. Derived from the word “cornu”, the cornea was first characterized as a hard structure etymologically related to an animal horn. The transparent and seemingly delicate anterior surface of the eye has contributed to major discoveries in the field of angiogenesis and, more recently, lymphangiogenesis (Alitalo et al., 2005; Lohela et al., 2009, 2003) (Table 1).

Judah Folkman proposed the hypothesis that the growth of cancerous tumors depends on angiogenesis (Folkman, 1971). His proposal of anti-angiogenesis cancer therapies in 1971 led to major discoveries of angiogenesis inhibitors. His group described the first experimental corneal angiogenesis model demonstrating that tumors implanted into the stromal layers at various distances from the limbus of the rabbit cornea can induce neovascularization, as opposed to merely inducing vessel dilation (Gimbrone et al., 1974). These experiments were followed by the micropocket pellet assays used to influence specific molecules/proteins involved in angiogenesis (Langer and Folkman, 1976) and corneal chemical and suture induced injury, which more closely mimic the complex nature of human diseases (Montezuma et al., 2009; Norrby, 2006; Rogers et al., 2007).

The maintenance of corneal avascularity has recently been termed ‘angiogenic privilege’ (Azar, 2006). This terminology mirrors the special protection the cornea enjoys against the immune rejection of grafted tissues, called ‘immune privilege.’ Just as most parts of the body do not have special protection against immune rejection of foreign antigens, the ‘angiogenic privilege’ designation implies that the absence of blood vessels in the

Table 1
Milestones in corneal angiogenesis/lymphangiogenesis research.

1627	First description of lymphatic vasculature	(Asellius, 1627)
1787	First use of the term angiogenesis	(Hunter, 1787)
1939	Laboratory studies of angiogenesis	(Ide et al., 1939)
1971	Hypothesis of angiogenesis and anti-angiogenesis	(Folkman, 1971)
1974	First experimental model of corneal angiogenesis	(Gimbrone et al., 1974)
1976	First use of micropocket pellet assay of corneal angiogenesis	(Langer and Folkman, 1976)
1989	Vascular endothelial growth factor sequenced	(Leung et al., 1989)
1994	Angiostatin	(O'Reilly et al., 1994)
1995	First lymphatic endothelial cell marker (FLT4/VEGFR-3)	(Kaipainen et al., 1995)
1997	Endostatin	(O'Reilly et al., 1997)
1999	Discover lymphatic vessel hyaluronan (HA) receptor-1 (LYVE-1) marker	(Banerji et al., 1999)
2002	Corneal lymphangiogenesis model to dissociate from angiogenesis	(Chang et al., 2002)
2006	Corneal angiogenic privilege	(Azar, 2006)
2006	VEGF trap hypothesis for corneal avascularity	(Ambati et al., 2006; Cursiefen et al., 2006a)

Download English Version:

<https://daneshyari.com/en/article/4032093>

Download Persian Version:

<https://daneshyari.com/article/4032093>

[Daneshyari.com](https://daneshyari.com)